Tty Biopharm Company Limited · TPEX:4105
Tty Biopharm — Q1 2026 Earnings Presentation
14 slides from Tty Biopharm's earnings presentation, May 27, 2026
Slide 1: TTY Biopharm Q1/2026 Operational Results Report
TTY Biopharm 4105 Q1/2026 Operational Results Report 2026.05.27
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, TTY Biopharm cautions that this foregoing list of factors is not ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’,
Slide 3: Q1/2026 Operational Highlights
Operational Results Report Q1/2026 Operational Highlights Q1/2026 Financial Performance 01 Q1/2026 Operational Highlights 2026 Outlook 2
Slide 4: TTY Strategy Enhances Operational Performance
TTY Strategy Enhances Operational Performance Operational Results Report Revenue Overview Q1/2026 Operational Unit：Million Highlights Consolidated Revenue 2,000 2 YoY growth +4.2% 1.52 billion Q1/2026 1,459 1,520 1.78 1,500 Financial Performance 1,000 1.57 1.5 Consolidated Operating Profit 2026 Outl
Slide 5: Q1/2026 Operational Highlights
Q1/2026 Operational Highlights Operational Results Report Q1/2026 Operational Highlights Q1/2026 Financial Performance 2026 Outlook Significant Achievements in Self- Introducing New International Developed and Domestically Produced Drugs to Improve Product Portfolio Strong Growth in Overseas Sales N
Slide 6: Q1/2026 Revenue Performance of BUs
Q1/2026 Revenue Performance of BUs Operational Results Report Revenue (NT Mn) Lonsurf 700,000 YoY UFur Q1/2026 +6.9% Operational 600,000 Highlights 500,000 US Lipo-AB Q1/2026 400,000 YoY Korea YONDELIS Financial Performance +6.3% 0.0% 0.1% 300,000 2026 Outlook 200,000 100,000 YoY +9.7% - Oncology In
Slide 7: Three Arrows of Operation with Outstanding Results
Three Arrows of Operation with Outstanding Results Operational Results Report Q1/2026 Operational Highlights Q1/2026 Financial Performance 2026 Outlook 6
Slide 8: Product Pipeline: Self-develop, License-in, Cooperation
Product Pipeline: Self-develop, License-in, Cooperation Operational Results Report Oncology 2025 2026 2027 2028 2029 Pulmivex XPOVIO Q1/2026 T1502 Operational Highlights T1508 T5260 T1509/T3505 Q1/2026 Financial Performance Intensive Care 2025 2026 2027 2028 Cubiyo 2026 Outlook TTY_3T TTY_3D T5250 T
Slide 9: Q1/2026 Financial Performance
Operational Results Report Q1/2026 Operational Highlights Q1/2026 Financial Performance 02 Q1/2026 Financial Performance 2026 Outlook 8
Slide 10: Q1/2026 Financial Performance
Q1/2026 Financial Performance Operational Results Report Income Statement YoY YoY （Unit: NT Thousand） 2026 Q1 2025 Q1 Differences % Financial Performance Q1/2026 Net Sales 1,520,487 1,458,850 61,637 4.2% • YoY consolidated revenue was 1.52 billion, +4.2% Operational due to the growth of Oncology BU
Slide 11: Q1/2026 Steady Revenue Growth
Q1/2026 Steady Revenue Growth Operational Results Report Q1/2026 Revenue Breakdown Q1/2026 Revenue Growth Q1/2026 Operational Highlights BUs % Revenue (NT Mn) 1,540 18.4% -1 Oncology 1,520 1 Q1/2026 4 1,520 39.7% 18 Financial 3.3% Intensive Care 1,500 Performance 39 1,480 Healthcare 19.9% 1,460 2026
Slide 12: 2026 Outlook
Operational Results Report Q1/2026 Operational Highlights Q1/2026 Financial Performance 03 2026 Outlook 2026 Outlook 11
Slide 13: Core Strategy and the Three Arrows are Implemented
Core Strategy and the Three Arrows are Implemented Operational Results Report Strengthen Global Deployment Q1/2026 Operational Highlights International Regulations 1 License-in the International New Drugs Q1/2026 R&D Potentials Financial 2 Performance Strengthen Local Clinical Collaborations 2026 Ou
Slide 14: 2026 Key Tasks
2026 Kay Tasks Operational Results Report 1 • Lipo-AB: -Expected to obtain licenses from Saudi Arabia, Australia, and Jordan -Deploy the market in Southeast Asia and South Q1/2026 Expanding collaboration & America Operational • Leavdo launched in Singapore Highlights overseas market • Continue to cu